80 related articles for article (PubMed ID: 10599961)
1. Hemostasis management by use of Hepcon/HMS: increased bleeding without increased need for blood transfusion.
Beholz S; Grubitzsch H; Bergmann B; Wollert HG; Eckel L
Thorac Cardiovasc Surg; 1999 Oct; 47(5):322-7. PubMed ID: 10599961
[TBL] [Abstract][Full Text] [Related]
2. [Clinical evaluation of heparin concentration and activated clotting time monitoring (HEPCON HMS) system].
Sakurada T; Kikuchi Y; Koushima R; Nakashima S; Hachiro Y; Kagaya H
Nihon Kyobu Geka Gakkai Zasshi; 1997 Jun; 45(6):836-40. PubMed ID: 9217380
[TBL] [Abstract][Full Text] [Related]
3. [A clinical evaluation of the Hepcon/HMS: a new device of monitoring hemostasis management during cardiopulmonary bypass].
Yamanishi H; Watanabe S; Hayashi K; Tomioka H; Minami M; Nozaki Y; Aoki T; Kawai Y; Kishino K; Ohta S
Kyobu Geka; 1997 Jun; 50(6):459-62. PubMed ID: 9185440
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device.
Noui N; Zogheib E; Walczak K; Werbrouck A; Amar AB; Dupont H; Caus T; Remadi JP
Perfusion; 2012 May; 27(3):214-20. PubMed ID: 22301392
[TBL] [Abstract][Full Text] [Related]
5. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS
J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
[TBL] [Abstract][Full Text] [Related]
6. Management of postoperative heparin rebound following cardiopulmonary bypass.
Pifarré R; Babka R; Sullivan HJ; Montoya A; Bakhos M; El-Etr A
J Thorac Cardiovasc Surg; 1981 Mar; 81(3):378-81. PubMed ID: 7464201
[TBL] [Abstract][Full Text] [Related]
7. Activated clotting time, anticoagulation, use of heparin, and thrombin activation during extracorporeal circulation: changes under aprotinin therapy.
Feindt P; Volkmer I; Seyfert U; Huwer H; Kalweit G; Gams E
Thorac Cardiovasc Surg; 1993 Feb; 41(1):9-15. PubMed ID: 7690165
[TBL] [Abstract][Full Text] [Related]
8. Perioperative coagulation management and blood conservation in cardiac surgery: a Canadian Survey.
Taneja R; Fernandes P; Marwaha G; Cheng D; Bainbridge D
J Cardiothorac Vasc Anesth; 2008 Oct; 22(5):662-9. PubMed ID: 18922420
[TBL] [Abstract][Full Text] [Related]
9. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
[TBL] [Abstract][Full Text] [Related]
10. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
[TBL] [Abstract][Full Text] [Related]
11. [Control of temporary anticoagulation in extracorporeal circulation using activated coagulation time].
Kessler G; Grünes G
Anaesthesist; 1984 Dec; 33(12):588-91. PubMed ID: 6528961
[TBL] [Abstract][Full Text] [Related]
12. [Use of high doses of aprotinin in cardiac surgery].
Carrera A; Martínez MV; García-Guiral M; Herrero E; Peral A; Planas A
Rev Esp Anestesiol Reanim; 1994; 41(1):13-9. PubMed ID: 7517058
[TBL] [Abstract][Full Text] [Related]
13. Intraoperative Monitoring of Heparin: Comparison of Activated Coagulation Time and Whole Blood Heparin Measurements by Different Point-of-Care Devices with Heparin Concentration by Laboratory-Performed Plasma Anti-Xa Assay.
Thompson TZ; Kunak RL; Savage NM; Agarwal S; Chazelle J; Singh G
Lab Med; 2019 Oct; 50(4):348-356. PubMed ID: 31053856
[TBL] [Abstract][Full Text] [Related]
14. [Effects of low doses of aprotinin in heart surgery].
Blanco E; Blanco J; Bóveda S; Sierra J; Rubio J; Durán D; Alvarez J
Rev Esp Anestesiol Reanim; 1994; 41(3):168-71. PubMed ID: 7520188
[TBL] [Abstract][Full Text] [Related]
15. The impact of aprotinin on blood loss and blood transfusion in off-pump coronary artery bypass grafting.
Bittner HB; Lemke J; Lange M; Rastan A; Mohr FW
Ann Thorac Surg; 2008 May; 85(5):1662-8. PubMed ID: 18442562
[TBL] [Abstract][Full Text] [Related]
16. Living without aprotinin: the results of a 5-year blood saving program in cardiac surgery.
Ranucci M; Castelvecchio S; Romitti F; Isgrò G; Ballotta A; Conti D
Acta Anaesthesiol Scand; 2009 May; 53(5):573-80. PubMed ID: 19173686
[TBL] [Abstract][Full Text] [Related]
17. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X.
Hardy JF; Bélisle S; Robitaille D; Perrault J; Roy M; Gagnon L
J Thorac Cardiovasc Surg; 1996 Jul; 112(1):154-61. PubMed ID: 8691862
[TBL] [Abstract][Full Text] [Related]
18. Reappearance of circulating heparin in whole blood heparin concentration-based management does not correlate with postoperative bleeding after cardiac surgery.
Ichikawa J; Kodaka M; Nishiyama K; Hirasaki Y; Ozaki M; Komori M
J Cardiothorac Vasc Anesth; 2014 Aug; 28(4):1003-7. PubMed ID: 24508375
[TBL] [Abstract][Full Text] [Related]
19. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
Kim YS; Murkin JM; Adams SJ
Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695
[TBL] [Abstract][Full Text] [Related]
20. Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination?
Bulutcu FS; Ozbek U; Polat B; Yalçin Y; Karaci AR; Bayindir O
Paediatr Anaesth; 2005 Jan; 15(1):41-6. PubMed ID: 15649162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
